Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Todos medical ltd. save search
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Published: 2022-06-30 (Crawled : 12:00) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 0.0%
H: 0.75%
C: 0.75%
covid-19 trial tollovir positive biomarkers phase 2
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
Published: 2022-05-27 (Crawled : 13:00) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 0.82%
H: 15.45%
C: 14.63%
covid-19 conference trial tollovir phase 2
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Published: 2022-01-27 (Crawled : 14:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 12.52%
H: 7.57%
C: -22.72%
covid-19 treatment phase 2 trial covid tollovir antiviral
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 10.0%
H: 7.27%
C: -1.82%
covid-19 treatment phase 2 trial covid tollovir
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Published: 2022-01-12 (Crawled : 15:00) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 5.45%
H: 20.83%
C: 1.67%
covid-19 treatment phase 2 trial covid tollovir topline results results topline
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Published: 2021-12-23 (Crawled : 14:00) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: -0.43%
H: 0.43%
C: -6.07%
phase 2 ceo approval covid covid test tollovir test
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Published: 2021-12-02 (Crawled : 12:00) - biospace.com/
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 5.24%
H: 16.05%
C: 1.93%
phase 2 trial covid tollovir enroll
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Published: 2021-11-19 (Crawled : 13:00) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: 10.19%
H: 4.3%
C: -3.23%
covid phase 2 antiviral trial tollovir enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.78 52.14% 15M
|
SYRA | $1.5 51.23% 1M
|
n/a
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
TROO | $1.41 29.36% 280K
|
Manufacturing
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.